It was analyzed that Hanmi Pharmaceutical's IMD 'Esomezol' which entered the U.S. market late last year, is recording poor sales

It was analyzed that Hanmi Pharmaceutical's IMD 'Esomezol' (anti-ulcer agent) which entered the U.S. market late last year, is recording poor sales.

On July 4, according to the business analysis report of Daewoo Securities Company, sales of Esomezol in the U.S. falls short of its initial expectation, even though the launch of Ranbaxy's first generic of Nexium is being delayed.

The report expe...